Lead sponsor
Genentech, Inc.
8 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
8
Trials led
0
Ongoing
2,031
Total enrollment
267
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
2
Phase 2
6
Trials by status
Completed
7
Terminated
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Diseaseprodromal ADPh 2Terminated457
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)Alzheimer's diseasePh 2Completed448
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With CrenezumabAlzheimer's diseasePh 2Completed360
A Study of Semorinemab in Patients With Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed272
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier CohortPSEN1 mutation requiredPh 2Completed252
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed91
A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Diseasemild-to-moderate ADPh 1Completed77
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's DiseaseAlzheimer's diseasePh 1Completed74